Because you only get one shot at this readout.
Methodology and software are not the hard part; judgment is. Pentara is the layer in between: senior statisticians who find the truth in your data, and who know from two decades of regulatory review what it takes to make that truth hold.
Our team's statistical expertise transforms complex data into actionable insights. We identify hidden patterns and correlations, providing an evidence-based perspective on any data-driven challenge. Our skills and systems allow us to complete projects two to three times faster than our competitors.
2–3× faster delivery
The integrity of data is the foundation of reliable analysis. Our commitment to rigorous data standards ensures every dataset we handle is meticulously cleaned and validated. We implement robust protocols to guarantee accuracy and clarity, a solid foundation for trustworthy insights and confident decisions.
CDISC Gold member · ALCOA+
We see ourselves as more than a service provider. By working closely with your team, we gain a deep understanding of your unique challenges and goals. That collaborative approach lets us deliver tailored solutions that answer your questions and empower you with the insights needed to achieve them.
Senior statisticians, directly
Pentara invests its own resources to advance research in Alzheimer's and other neurodegenerative diseases. Without government or pharmaceutical industry funding, we maintain unbiased expertise and accelerate effective treatments wherever they emerge.
That independence is why we can publish statistical methodology openly and provide expert insights to both companies developing therapies and the regulatory agencies reviewing them.
ADCOMS
Detecting decline in prodromal and mild Alzheimer's disease, where single scales barely move over 18 months.
Publication → (opens in a new tab)iADRS
One score for cognition and function, so an effect on both does not split into two underpowered tests.
Publication → (opens in a new tab)APCC
Tracking cognitive change in people who do not yet have symptoms, for prevention trials.
Publication → (opens in a new tab)GST
Testing a treatment across many endpoints at once when no single endpoint can be powered on its own.
Poster (PDF) → (opens in a new tab)TCT
Expressing an effect as time saved, so "slowed decline" means something to a patient and to a reviewer.
Publication → (opens in a new tab)The category
Measuring change in slow, heterogeneous, hard-to-measure disease. That's the problem these exist to solve, and it's the only thing we've done for twenty-five years.
Browse the publicationsThe earlier a statistician joins, the more design decisions stay open. But we regularly step in mid-study, and even after a first pass has gone wrong. The goal never changes: get the treatment to the patients waiting for it as quickly as a good trial and a well-prepared FDA presentation allow.
Before first patient
Sample size, outcomes, and adaptive design set up to detect a real effect.
Study Design →During conduct
Continuous cleaning, edit checks, and reconciliation before database lock.
Data Management →Risk control
Blinded anomaly detection that protects your observed effect size.
Data Quality Protection →When it goes wrong
Independent oversight to diagnose issues and get back through the gates.
Regulatory Support →Thirty minutes on your endpoint, or a fixed-scope read of your SAP before it locks. Both start with one message.
